ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Lucid Diagnostics (LUCD)
Lucid Diagnostics stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
$0.44▼ -12.57%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
41%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Lucid Diagnostics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Lucid Diagnostics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Lucid Diagnostics a 41% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.31 and $0.52; in 9 out of 10, between $0.20 and $0.82. Estimated annual volatility is 165%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $120M
- 52-week high
- $1.63
- 52-week low
- $0.30
- Revenue (12 months)
- $5.4M
- Revenue growth (YoY)
- +8.3%
- Gross margin
- -41.7%
- Free cash flow (12 months)
- $-26.4M
- Beta
- 1.10
What this means
ATLAS does not publish a fair value for LUCD right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks LUCD has traded between $0.30 and $1.63. Today it is 73.1% below that high and 47% above its low.
Its beta is 1.10: it moves roughly in line with the market.
About the company
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD.
Want to see everything about Lucid Diagnostics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Lucid Diagnostics do?
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD.
What is the chance LUCD goes up next month?
41%: somewhat worse than a coin flip. In half of the simulated outcomes, LUCD ends the month between $0.31 and $0.52.
How big is Lucid Diagnostics and what is its P/E ratio?
Lucid Diagnostics's market capitalization is $120M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is LUCD?
ATLAS estimates annual volatility at 165%. In a typical month, half of the outcomes end between $0.31 and $0.52.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer